Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02873819
Other study ID # GL0817-01
Secondary ID 2016-001256-22
Status Completed
Phase Phase 2
First received
Last updated
Start date March 30, 2017
Est. completion date May 25, 2021

Study information

Verified date September 2020
Source Gliknik Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date May 25, 2021
Est. primary completion date May 17, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age > 18 years 2. Histologic diagnosis of squamous cell carcinoma of the oral cavity including the lip, floor of mouth, anterior 2/3 of tongue, alveolus and gingiva, buccal mucosa, hard palate and retromolar trigone 3. Subjects must have undergone primary gross total resection (no re-resected patients are allowed) with fulfillment of at least 1 of the following histologic criteria for high-risk disease: - Histologic involvement of 2 or more regional lymph nodes - Any lymph node with histologic extracapsular extension (ECS) - Close (<3mm) or positive surgical margins on microscopic evaluation with no gross residual tumor 4. No evidence of locoregional disease or distant metastases at screening. Subjects must have negative scans (CT, CT-PET or MRI) for locoregional recurrence, brain or lung metastases. A negative biopsy will be mandated in patients with a positive scan. Other evaluations should be performed as clinically indicated. 5. No history of distant metastases. 6. Tumor tissue from surgery or biopsy must be available to determine MAGE-A3 expression for correlative studies. 7. Following surgery, the patient must have received external beam radiotherapy (58-66 Gy in 2 Gy fractions, 5 days per week) with concomitant cisplatin starting within 8 weeks of surgery. A brief delay in the initiation of radiotherapy following 8 weeks post-surgery due to administrative reasons (e.g., start of RT on Mondays) may be permitted by the Medical Monitor. The cumulative dose of cisplatin the subject received must be > 150 mg/m2. Protocol therapy must be initiated within a period of 4-8 weeks (28-56 days) following the end of RT. 8. The patient is, in the investigator's opinion, adequately recovered from the effects of surgery and chemoradiotherapy to participate in this study. 9. Blood HLA-A2 phenotype 10. ECOG Performance Status < 1 11. Laboratory values obtained = 14 days prior to randomization: - Absolute neutrophil count (ANC) = 1500/µL (without intervention, e.g., G-CSF) - Platelets = 75,000/µL (without intervention, e.g., transfusion) - Hemoglobin = 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb =8.0 g/dl is acceptable). - Alkaline phosphatase = 2.5 x upper limit of normal (ULN) - AST and ALT = 2 x ULN - Creatinine < 2 x ULN - Bilirubin < 1.5x ULN (except for patients with Gilbert's disease, for whom the upper acceptable limit of serum bilirubin is 3mg/dL) 12. A female subject is eligible to enter the study if she is: - not pregnant or nursing; Female participants must not breastfeed during the study and for a period of 30 days following the last dose. - of non-childbearing potential (i.e., women who had a hysterectomy, are postmenopausal which is defined as 1 year without menses, have both ovaries surgically removed or have current documented tubal ligation); or - of childbearing potential (i.e., women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhea [even severe], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at screening, and agree to one of the following: - complete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent and 6 months after the last dose of study agent; or - consistent and correct use of 1 of the following highly effective methods of birth control for one month prior to the start of the study agent and 6 months after the last dose: - combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) - progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) - intrauterine device (IUD) - intrauterine hormone-releasing system ( IUS) - bilateral tubal occlusion - vasectomized partner (if vasectomized is the sole sexual partner and has received medical confirmation of surgical success) 13. A male subject who is sexually active with a woman of childbearing potential is eligible to enter the study if he agrees to use effective contraception throughout the study and for 6 months after the last dose of study agent. 14. The subject must be capable of understanding the investigational nature, potential risks and benefits of the study and capable of providing valid informed consent. The subject must provide study specific informed consent prior to any protocol procedures that are not a part of standard care, including consent for assessment of HLA-A2 status, mandatory tissue submission for MAGE-A3 analysis and correlative studies. 15. The subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol. Exclusion Criteria: 1. Known HIV or hepatitis B/C infection (testing not required). Subjects who are hepatitis C antibody positive may be enrolled if they are confirmed to have a negative viral load at screening. 2. Subjects with active autoimmune disease or a history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment. 3. Subjects who have used systemic corticosteroids or other immunosuppressants for any condition within 14 days of randomization. Inhaled or topical steroids are permitted. 4. Any medical condition which would, in the investigator's opinion, compromise the patient's ability to mount an immune response, renders the patient a poor candidate for this trial or could confound the results of the study 5. Major surgery or traumatic injury within 28 days of randomization 6. Prior splenectomy or organ allograft 7. Any other prior, concurrent or planned chemotherapy, immunotherapy, radiotherapy, device, or investigational therapy for this cancer other than those specified in this study. 8. History of other malignancy (i.e., excluding disease under study) within 3 years of randomization. Exceptions include: adequately-treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or adequately treated non-metastatic prostate cancer. 9. Known hypersensitivity to GM-CSF, yeast-derived products or any component of the GM-CSF drug product (e.g., mannitol) or poly-ICLC (e.g., carboxymethylcellulose). 10. Known hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GL-0817
GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
Hiltonol
Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
Sargramostim
Sargramostim will be administered intramuscularly at the dose of 100 µg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
cyclophosphamide
cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
Placebo
Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration

Locations

Country Name City State
Hungary National Institute of Oncology Budapest
Hungary Semmelweis University Budapest
Hungary University of Debrecen Clinical Center Debrecen
Hungary Bacs-Kiskun County Teaching Hospital Kecskemét
Hungary Medical Center of the University of Pecs Pecs
Poland Oncology Center of Prof. Franciszek Lukaszczyk in Bydgoszcz Bydgoszcz
Poland Swietokrzyskie Oncology Center in Kielce Kielce
Russian Federation Clinical Oncology Center Omsk
Russian Federation Rostov Oncology Research Institute Rostov-on-Don
Russian Federation Leningrad Regional Oncology Center Saint Petersburg
Russian Federation Oncology Center of Moskovskiy District Saint Petersburg
Russian Federation Ogarev Mordovia State University Saransk
Russian Federation Clinical Hospital #1 Sterlitamak
Russian Federation Republican Clinical Oncology Center Ufa
Russian Federation Regional Clinical Oncology Hospital Yaroslavl
Serbia Institute of Oncology and Radiology of Serbia Belgrade
Serbia Military Medical Academy, Clinic of Maxillofacial Surgery Belgrade
Serbia Oncology Institute of Vojvodina (IOV), Clinic of Medical Oncology Sremska Kamenica
Spain University Hospital Vall d'Hebron (HUVH) Barcelona
Spain University Hospital La Paz Madrid
Spain Parc Tauli Health Corporation Sabadell
Ukraine Cherkasy Regional Oncology Center Cherkasy
Ukraine Chernihiv Regional Oncology Center Chernihiv
Ukraine Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital Dnipro
Ukraine Ivano-Frankivsk Regional Oncology Center Ivano-Frankivsk
Ukraine Communal Non-profit enterprise "Regional Center of Oncology" Kharkiv
Ukraine Kyiv Regional Oncology Center Kyiv
Ukraine Lviv Regional Clinical Hospital Lviv
Ukraine Odesa Regional Oncology Center Odesa
Ukraine Poltava Regional Clinical Oncology Center Poltava
Ukraine Sumy Regional Clinical Oncology Center Sumy
Ukraine Podillia Regional Oncology Center Vinnytsia
United States University of Maryland Greenebaum Cancer Center Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Gliknik Inc.

Countries where clinical trial is conducted

United States,  Hungary,  Poland,  Russian Federation,  Serbia,  Spain,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free interval Up to 2 years
Secondary Disease-free survival (DFS) up to 2 years
Secondary Overall survival (OS) up to 5 years
Secondary Disease-free interval in a per protocol analysis up to 2 years
Secondary Adverse event profile up to week 94
See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Active, not recruiting NCT03721757 - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Phase 2
Active, not recruiting NCT04387682 - Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients N/A
Completed NCT01321892 - Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium N/A
Completed NCT01636544 - Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity N/A
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Withdrawn NCT04831450 - Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2
Recruiting NCT04191460 - Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Phase 2
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Terminated NCT01077869 - A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis Phase 1
Completed NCT02609386 - IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity Phase 2
Not yet recruiting NCT05452408 - Antitumor-B KAC PK Study Phase 1
Not yet recruiting NCT03364166 - Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma N/A
Terminated NCT02331875 - Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity Phase 1/Phase 2
Completed NCT01265849 - Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03575598 - Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study Early Phase 1
Active, not recruiting NCT03459729 - Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer Early Phase 1